Medical Disorders
Basic InformationLookupsLatest News
Drop in Life Expectancy From COVID Much Worse for Black, Hispanic AmericansInnovative Kidney Donor 'Voucher' System Is Saving LivesMental Confusion an Early Warning Sign of Severe COVID-19COVID Caused Biggest Drop in U.S. Life Expectancy Since World War IIClot-Removing Procedure Can Sometimes Backfire for Stroke PatientsFDA to Add Warning to Pfizer, Moderna Vaccines About Rare Heart Issues in YoungAHA News: Silent Heart Attacks All Too Common, and Often OverlookedRash, Itch After COVID Vaccine Rare & Quickly ResolvesStudy Suggests COVID Vaccine Booster Shots Will Be NeededNo Need for Blood Thinners in Patients Sick at Home With COVID-19Heart Issues in Young COVID Vaccine Recipients Rare, Usually Mild and Quickly Resolve: ExpertsMore E-Scooter Rideshares, More InjuriesMore Than Half of People With Asthma Aren't Seeing a SpecialistAutopsy Study Shows How COVID Harms the BrainCOVID Deaths Drop to New Lows in U.S., While Vaccination Rates ClimbNot-So-Happy-Birthdays: Parties Helped Spread COVID, Study FindsAHA News: Should Rare Cases of Heart Inflammation Put Your COVID-19 Vaccine Plans on Hold?Obesity in Teens Raises Adult Diabetes Risk, Even After Weight LossNew Genetic Insights Into Cause of ALSScreen All Kids for Heart Problems, Pediatricians' Group SaysIn 11 States, Seniors' Low Vaccination Rates a 'Powder Keg' for New CasesSickle Cell Plagues Many Black Americans, But There's Hope for Better TreatmentsSurvivors' Plasma Helps Blood Cancer Patients Battle COVID-19Hospitals: One Reason COVID Is More Lethal for Black AmericansMany 'High Priority' Patients Aren't Getting Put on Kidney Transplant ListsU.S. to Spend $3.2 Billion to Help Develop Antiviral Pills for COVIDRed Cross Warns of Severe Blood ShortageHand Sanitizer Vapors Can Cause Nausea, DizzinessPfizer, Moderna Vaccines Do No Harm to Male Fertility: StudyLess Than 1% of People Who've Had Severe COVID Get Re-InfectedMold a Big Threat to People With COPDWhat Works Best to Ease Migraines?Pandemic Silver Lining: Fewer Dangerous Flare-Ups for COPD PatientsIs Zinc a Friend or Foe to Kidney Stones?Strict Rest Not Recommended After Sports-Linked Concussion, Experts SayEven Good Weather Didn't Lift Lockdown Blues: StudyU.S. ​COVID Death Toll Tops 600,000Third Dose of COVID Vaccine Boosts Protection in Transplant RecipientsCould a Type of Statin Raise Dementia Risks?Many U.S. Seniors May Need Better Knee Arthritis CareAfter COVID, Many Americans Are Struck by New Maladies: StudyCataracts: Common, and Easy to TreatThere Are Many Good Reasons for Kids to Get the COVID VaccineBabies Produce Strong Immune Response to Ward Off COVID-19: StudyNovavax's COVID Vaccine Shines in Latest TrialAHA News: U.S. Appears to Lose Ground in Controlling High Blood PressureWeight-Loss Surgeries Used Least in U.S. States That Need Them MostObesity Could Raise Odds for 'Long-Haul' COVID SymptomsSmokers, Obese People Need Major Heart Interventions Earlier in LifeOld Age No Bar to Successful Heart Transplant, Study Finds
Questions and AnswersVideosLinksBook Reviews
Related Topics

Men's Health
Women's Health

Experimental Treatment Offers New Hope Against Lupus

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: May 27th 2021

new article illustration

THURSDAY, May 27, 2021 (HealthDay News) -- An experimental antibody therapy may help ease skin symptoms from the autoimmune disease lupus, a small preliminary trial suggests.

Researchers found that a higher-dose version of the drug spurred a "clinically meaningful" symptom improvement for 87% of patients after one month.

But they also stressed that the findings are based on a small "phase 1" trial — a type of study designed primarily to gauge a treatment's safety.

The safety findings were "encouraging," and there were "some hints of clinical benefit," said lead researcher Jodi Karnell, a senior director of research at Horizon Therapeutics, the company developing the drug.

Now, she said, larger trials are needed to confirm that the therapy works.

The drug, known for now as VIB7734, is a monoclonal antibody — a lab-made protein that acts like an immune system antibody. Such antibodies can be directed against specific substances in the body that are involved in a disease process.

Lupus is caused by an autoimmune reaction, where the immune system mistakenly attacks the body's own tissue.

The most common form is systemic lupus, which can spur inflammation throughout the body, including the skin, joints, kidneys, blood vessels and brain.

Another form, called cutaneous lupus, affects only the skin, causing rashes and sores, often on the face and scalp.

There are treatments for those skin symptoms, including anti-inflammatory corticosteroids; antimalarial medications, which alter the immune response; and immune-suppressing drugs like methotrexate.

But those treatments can have significant side effects, and they don't always work, Karnell pointed out.

"There's a large unmet need," she said.

In the United States alone, about 1.5 million people have lupus, according to the Lupus Foundation of America.

One monoclonal antibody is approved for systemic lupus, called Benlysta (Belimumab). It blocks an immune system protein involved in creating auto-antibodies (antibodies that attack the body's tissue).

The new monoclonal antibody works in a different way, Karnell explained. It depletes immune system cells called plasmacytoid dendritic cells.

Those cells normally fight infection by releasing inflammatory chemicals, including type 1 interferons. But uncontrolled activity in the cells, pumping out too much interferon, is thought to contribute to autoimmune diseases.

For the phase 1 trial, Karnell's team recruited 31 patients with at least one of several autoimmune conditions, including systemic and cutaneous lupus. They were randomly assigned to receive injections of either the monoclonal antibody, at various doses, or a placebo. The injections were given every four weeks, for a total of three.

After one month, the group on the highest antibody dose showed the biggest benefit: seven of eight (87.5%) had a "clinically meaningful" reduction in skin symptoms, compared to about 37% of patients on a lower dose, and 28% of placebo patients.

The findings were published May 26 in the journal Science Translational Medicine.

Dr. Donald Thomas, a rheumatologist who was not involved in the study, sounded a note of caution: Over the years, various lupus therapies have initially showed promise only to disappoint in late-stage trials.

That said, these early results are encouraging, he noted.

"If they bear out in phase 2 and 3 trials, this would be a game-changer," said Thomas, of Uniformed Services University of the Health Sciences, and Arthritis and Pain Associates of PG County, in Maryland.

Cutaneous lupus can take a toll on patients' quality of life, Thomas said, with some having hair loss and scarring from skin lesions.

Unlike therapies that take broad aim on the immune system, monoclonal antibodies target specific components of the immune response, Thomas said. That means they may have fewer side effects and be more effective.

Thomas noted that side effects with Benlysta, the antibody approved for SLE, have been "remarkably minimal" overall.

Karnell stressed that the experimental drug worked as intended — depleting dendritic cells and type 1 interferon activity in both the blood and patients' skin lesions. The next step is a larger phase 2 trial, she added.

The researchers also found that patients with high interferon activity to start were the ones whose symptoms improved with the antibody. So one question for the future, Karnell said, is whether measuring patients' interferon activity can help identify those most likely to benefit from the treatment.

If doctors were able to do that, it would be an advance, according to Thomas.

Right now, he said, lupus treatment often involves trial-and-error to figure out which therapy works — a frustrating fact for patients.

More information

The Lupus Foundation of America has more on lupus treatment options.

SOURCES: Jodi Karnell, PhD, a senior director, research group, Horizon Therapeutics, Dublin, Ireland/Deerfield, Ill.; Donald Thomas Jr., MD, associate professor, medicine, Uniformed Services University of the Health Sciences, Bethesda, Md., and rheumatologist, Arthritis and Pain Associates of PG County, Greenbelt, Md.; Science Translational Medicine, May 26, 2021, online


Amazon Smile


Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.


powered by centersite dot net